Blocking drugs such as Bic Enprenol tablets and raltegravir can be taken orally after 38 hours of high-risk behavior. 1. Bic Enprenol Tablets: indicated as a complete regimen for the treatment of adults with human immunodeficiency virus infection, is an integrase strand transfer inhibitor that inhibits the strand transfer activity of the HIV-1 integrase enzyme, thereby inhibiting the integrase enzyme, which can prevent linear DNA from integrating into the host genomic DNA, thus blocking the formation of the HIV-1 virus and viral proliferation. Bictegravir tablets are a combination formulation containing bictegravirna, emtricitabine, and tenofovir disoproxil fumarate per tablet. Adverse reactions include headache, diarrhea, and nausea. Hypersensitivity to the ingredients or excipients appears to be prohibited, prohibited from use prohibited from combining with rifampicin or St. John’s wort. 2. Raltegravir: It is indicated for the treatment of HIV-1 (human immunodeficiency virus) in combination with other anti-retroviral drugs. It can inhibit the catalytic activity of HIV integrase, an HIV-encoding enzyme known to be essential for viruses, preventing covalent insertion or integration of HIV genes into the host cell genome early in the infection. Adverse reactions include diarrhea, nausea, vomiting, headache, fatigue, and fever. This product is contraindicated in patients who are hypersensitive to any component of the product. After high-risk behavior, it is recommended to go to the hospital for examination first, follow the doctor’s advice to choose the medication, avoiding their own indiscriminate use of drugs.